drugset / Trial / NCT01832038

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

NCT01832038

Phase 3 Completed 473 enrolled UCB Pharma UCB Japan Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition Period of EP0008 \[NCT01710657\]

Timeline

Start
2013-03-26
Primary completion
2019-07-31
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 100 mg
Subject Lacosamide Other / unclassified 400 mg

Indications